Dexpramipexole dihydrochloride Catalog No.:M9926-2 including T315I

including T315I

2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

Dexpramipexole dihydrochloride Catalog No.:M9926-2 including T315IDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well